Published in Vaccine Weekly, July 13th, 2005
IMNR announced that clinical research conducted by the company in association with Oregon Health & Science University (OHSU) has indicated that FOXP3, a specific genetic marker on T-cells known to be involved in maintaining immune tolerance and regulation of autoimmune diseases, is significantly reduced in patients with MS compared to healthy controls.
These findings, published in the July issue of the Journal of Neuroscience Research, are significant because this deficiency of FOXP3 in MS patients is likely...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.